Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project

Tinelli, Michela; Pugliatti, Maura; Antonovici, Andreea; Hausmann, Bettina; Hellwig, Kerstin; Quoidbach, Vinciane; Sørensen, Per Soelberg

doi:10.1016/j.msard.2021.103107

Cited by 5 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, offsets of these treatment costs from savings of other healthcare resources [ 67 ] and maintained work capacity [ 6 ] have been suggested. Economic modelling also supports the notion that early initiation of treatment is cost saving to society [ 68 ]. This finding was robust across models, including a Sweden-specific model, and more costs were saved from averting MS the longer the time horizon [ 68 ].…”

Section: Discussionmentioning

confidence: 67%

“…Economic modelling also supports the notion that early initiation of treatment is cost saving to society [ 68 ]. This finding was robust across models, including a Sweden-specific model, and more costs were saved from averting MS the longer the time horizon [ 68 ]. Our relatively low excess healthcare costs of MS could also be influenced by rituximab being widely used off-label [ 17 ].…”

Section: Discussionmentioning

confidence: 67%

See 1 more Smart Citation

Excess costs of multiple sclerosis: a register-based study in Sweden

et al. 2022

View full text Add to dashboard Cite

Background and objective Population-based estimates of the socioeconomic burden of multiple sclerosis (MS) are limited, especially regarding primary healthcare. This study aimed to estimate the excess costs of people with MS that could be attributed to their MS, including primary healthcare. Methods An observational study was conducted of the 2806 working-aged people with MS in Stockholm, Sweden and 28,060 propensity score matched references without MS. Register-based resource use was quantified for 2018. Annual healthcare costs (primary, specialised outpatient, and inpatient healthcare visits along with prescribed drugs) and productivity losses (operationalised by sickness absence and disability pension days) were quantified using bottom-up costing. The costs of people with MS were compared with those of the references using independent t-tests with bootstrapped 95% confidence intervals (CIs) to isolate the excess costs of MS from the mean difference. Results The mean annual excess costs of MS for healthcare were €7381 (95% CI 6991–7816) per person with MS with disease-modifying therapies as the largest component (€4262, 95% CI 4026–4497). There was a mean annual excess cost for primary healthcare of €695 (95% CI 585–832) per person with MS, comprising 9.4% of the excess healthcare costs of MS. The mean annual excess costs of MS for productivity losses were €13,173 (95% CI 12,325–14,019) per person with MS, predominately from disability pension (79.3%). Conclusions The socioeconomic burden of MS in Sweden from healthcare consumption and productivity losses was quantified, updating knowledge on the cost structure of the substantial excess costs of MS.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 67%

Excess costs of multiple sclerosis: a register-based study in Sweden

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, one study used a health economic model, to estimate costs and effects from MS, concluding that early treatment with DMTs was cost-effective. 42 …”

Section: Discussionmentioning

confidence: 99%

Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden

Karampampa

Gyllensten

Murley³

et al. 2022

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

Background Early treatment with disease modifying therapies (DMTs) for multiple sclerosis (MS) has been associated with lower disability progression; the aim was to explore its association with cost of illness (COI) in MS. Methods All people with relapsing-remitting MS in the Swedish MS register, aged 20–57 years and receiving their first MS DMT in 2006–2009, were followed in nationwide registers for 8 years. Healthcare costs (in- and outpatient healthcare, DMTs and other prescribed drugs), and productivity losses (sickness absence and disability pension) of individuals receiving therapy in ≤6 months after diagnosis (early treatment group) were compared to those receiving therapy >6 months (late treatment group). Using Poisson regressions, the mean COI per patient per year, and per group, was estimated, adjusted for disability progression. Results The early treatment group comprised 74% of the 1562 individuals included in the study. The early treatment group had lower productivity losses over time. Both groups had similar healthcare costs, which first increased and then decreased over time. Conclusions Early DMT in MS could result in lower productivity losses possibly through maintained work capacity. COI serves as an objective measure showing the advantage of early vs. late treatment initiation in MS.

show abstract

“…Moreover, given evidence implicating a role for 25-(OH) hydroxyvitamin D as early as in utero, we might propose implementing 25-(OH) hydroxyvitamin D in at risk patients during pregnancy and/or at birth/infancy. 25-(OH) hydroxyvitamin D is a relatively safe and cost-effective therapy (45,46) that has the potential to prevent MS, and like breast milk, has other potential health benefits.…”

Section: Environmental Risk Factors: the Role Of Sun And Serum 25-(oh...mentioning

confidence: 99%

Preventing Multiple Sclerosis: The Pediatric Perspective

et al. 2022

View full text Add to dashboard Cite

Pediatric-onset multiple sclerosis (MS) is a predominantly relapsing-remitting neuroinflammatory disorder characterized by frequent relapses and high magnetic resonance imaging (MRI) lesion burden early in the disease course. Current treatment for pediatric MS relies on early initiation of disease-modifying therapies designed to prevent relapses and slow progression of disability. When considering the concept of MS prevention, one can conceptualize primary prevention (population- or at-risk population interventions that prevent the earliest facet of MS pathobiology and hence reduce disease incidence), or secondary prevention (prevention of disease consequence, such as reducing relapse frequency and lesion accrual, enhancing focal lesion repair, promoting CNS resilience against the more global facets of disease injury, and ultimately, preventing progression of neurological disability). Studying the pediatric MS population provides a unique opportunity to explore early-life exposures that contribute to the development of MS including perinatal and environmental risk determinants. Research is ongoing related to targeting these risk factors for potential MS primary prevention. Here we review these key risk factors, their proposed role in the pathogenesis of MS, and their potential implications for primary MS prevention.

show abstract

Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project

Cited by 5 publications

References 37 publications

Excess costs of multiple sclerosis: a register-based study in Sweden

Excess costs of multiple sclerosis: a register-based study in Sweden

Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden

Preventing Multiple Sclerosis: The Pediatric Perspective

Contact Info

Product

Resources

About